Bile Acid Drug Class List

Drugs in Drug Class: Bile Acid

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lgm Pharma	CHENODIOL	chenodiol	TABLET;ORAL	091019-001	Oct 22, 2009		RX	No	Yes
Mirum	CHOLBAM	cholic acid	CAPSULE;ORAL	205750-001	Mar 17, 2015		RX	Yes	No
Mirum	CHOLBAM	cholic acid	CAPSULE;ORAL	205750-002	Mar 17, 2015		RX	Yes	Yes
Ajanta Pharma Ltd	CHOLESTYRAMINE	cholestyramine	POWDER;ORAL	211119-002	Apr 6, 2020	AB	RX	No	No

Market Dynamics and Patent Landscape for Bile Acid Drugs

Last updated: April 25, 2026

What is the “bile acid” drug class in commercial and regulatory terms?

“Bile acid” is not a single FDA or EMA therapeutic class. In practice, the market groups products by mechanism tied to bile acid homeostasis and enzymes/transporters in bile acid synthesis, conjugation, and enterohepatic circulation. Commercially, this usually maps to four clusters:

1. FXR (NR1H4) agonists (bile acid receptor signaling)
2. TGR5 (GPBAR1) agonists / bile-acid-related signaling through TGR5
3. Fibroblast growth factor 19 (FGF19) pathway modulation (bile acid synthesis suppression via FGF19/FGFR4)
4. Bile acid transport / bile acid binding and sequestration (including ileal transporter and intestinal binding concepts)

The most visible bile-acid-driven commercial franchise is FXR agonism in liver and cholestatic diseases; the rest of the market is smaller, with pipeline competition and frequent patent-expiry-driven entry risk.

---

How does the market behave across indications?

Where does revenue concentrate?

The strongest commercial demand for “bile acid” drugs concentrates in cholestatic and rare liver disease indications that have clear biomarker readouts linked to bile acid physiology (serum bile acids, alkaline phosphatase, pruritus scores, and liver inflammation markers).

Typical demand drivers:

• Biomarker-linked endpoints that de-risk development and speed payer coverage decisions.
• High unmet need in primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and cholestatic subtypes where standard-of-care does not fully address bile-acid-driven pathophysiology.
• Combination therapy logic: bile acid pathway drugs often slot alongside immunomodulators or anti-pruritics rather than replacing them outright.

What is the pricing and access pattern?

Pricing generally follows specialty liver care norms: high annual therapy cost with outcomes-based contracting in some geographies, and step edits around line-of-therapy and baseline disease severity.

The operational reality for investors:

• Payer access is tied to guideline-aligned endpoints (bilirubin, ALP, bile acid reductions, and itch).
• Sub-population differentiation matters (e.g., PBC vs PSC, pruritus phenotype, and prior response to ursodeoxycholic acid).

---

How competitive is the bile acid mechanism space?

FXR agonists: the dominant competitive battlefield

FXR agonists are the most crowded mechanism area because FXR sits at the center of bile acid feedback regulation. Competition is defined by:

• Potency and selectivity (hepatic FXR activation vs off-target profiles)
• Safety/tolerability (GI symptoms, lipid changes, liver enzyme dynamics)
• Chronic dosing durability (treatment is often long-duration)

Other bile-acid linked mechanisms: smaller but strategically important

TGR5 and FGF19 axis therapies are often advanced as:

• Alternative routes to bile acid suppression
• Or “add-on” options to improve pruritus or liver enzymes beyond FXR monotherapy
• Differentiated risk profiles for patient populations sensitive to FXR-related safety signals

---

What does the patent landscape look like (scope, duration, and entry risk)?

A “bile acid” patent landscape is usually structured in layers:

1. Core compound patents (composition of matter, typically 20-year term from earliest priority)
2. Polymorph, salt, and form patents (often 5 to 20 years after filing depending on priority chain)
3. Solid state and formulation patents (release profile, coating, stability, manufacturing methods)
4. Method-of-use patents tied to specific indications and dosing regimens
5. Combination patents (bile acid drug + background standard of care or symptomatic relief)

Because bile acid drugs treat chronic, high-value liver diseases, companies routinely build “evergreening” portfolios around:

• Patient selection (biomarker thresholds, genotype strata, disease stage)
• Dose schedules (titration and maintenance)
• Endpoints (itch scales, ALP reductions, and bile acid targets)

Patent expiry is often the near-term trigger for generic and follow-on competition

The practical entry risk for investors is not only compound expiry. It is:

• Whether late-form or method patents survive
• Whether patents are narrowly drafted (device of enforceability)
• Whether any approved “at-risk” entrants can design around formulation and dosing claims

---

Which landmark bile acid patents define the sector?

FXR agonist families: compound + method layers

The sector’s key legal leverage typically sits in:

• Composition of matter claims for the specific FXR ligand(s)
• Method-of-treatment claims for cholestatic or pruritus-linked diseases
• Dosing regimen claims that can block close substitutes even when chemical structures differ

What about FGF19 pathway assets?

FGF19 pathway programs tend to generate:

• Strong method claims tied to bile acid suppression outcomes
• Additional patent value in engineered proteins or modified peptides (depending on modality)
• Formulation protections if long-acting delivery is used

Bile acid sequestration and transporter targets

Transporter-related patents can also be enforceable when:

• Claims tie the therapy to specific patient populations and routes of administration
• The compound has limited off-target activity (enabling differentiation from broad “bile acid binding” claims)

---

How do clinical development and reimbursement shape patent strategy?

In bile acid therapy, patenting frequently tracks clinical proof:

• Early Phase II biomarkers (serum bile acids, ALP, pruritus) become method claim anchors.
• Late Phase III outcomes drive broader indications and claims for label-expanding uses.

Patent drafting tends to favor:

• Specific dosing frequency and titration schedules
• Combination use with background standard therapies
• Subgroup claims tied to disease subtype and prior treatment response

---

Key market outcomes investors watch for bile acid drugs

Commercial traction indicators

1. Speed to label expansion from initial indication into related cholestatic disorders
2. Durability of biomarker response (treatment continuation rate is a proxy for long-run value)
3. Pruritus outcomes (itch is a high-satisfaction endpoint for payers and patients)
4. Safety profile stability with chronic dosing

Patent-risk indicators

1. Listing density in relevant jurisdictions (US Orange Book-style listing, EP validation patterns)
2. Claim breadth for composition and method-of-use
3. Whether late patents are tied to measurable outcomes that match label language

---

Where are the patent landmines?

The biggest enforceability risks in bile acid portfolios:

• Indication narrowing: method claims only cover a specific disease subtype, leaving room for design-around in adjacent indications.
• Dosing claims: when claims require strict titration or daily dosing, a competitor can propose alternative regimens.
• Formulation dependency: if claims require a specific solid state, a competitor can seek a different polymorph or salt.
• Patent exhaustion arguments if a competitor uses an identical product and claim coverage is weak on use rather than substance.

---

What are the highest-value IP targets for new entrants?

For an entrant pursuing bile acid mechanisms, the highest economic value usually attaches to:

• First-in-class differentiation through selectivity and safety profile that supports broader label claims.
• Strong method-of-use coverage aligned to phase-3 endpoints and label wording.
• Long-acting or formulation advantages that justify additional formulation patents.
• Combination claim strategy to defend against substitution even after compound expiry.

---

Key Takeaways

• The “bile acid” market behaves like a chronic specialty liver franchise with strong demand for biomarker-linked endpoints.
• Competition is concentrated in FXR agonism, with additional strategic programs in the FGF19 axis and other bile-acid linked pathways.
• Patent value is multi-layered: composition, solid state/formulation, and method-of-use claims that track label endpoints.
• The near-term investment and entry-risk hinge is not only compound expiry but also survival of later method and formulation patents that match real-world prescribing.

---

FAQs

1. Is “bile acid” a formal drug class in labeling?
   No. It is a functional grouping used by industry based on bile-acid pathway mechanisms and related clinical indications.

2. Which bile acid mechanism dominates commercial competition?
   FXR agonists (NR1H4) are the most active and crowded mechanism area.

3. What patent types matter most for bile acid drugs?
   Composition-of-matter plus method-of-use claims aligned to label endpoints, with additional leverage from polymorph/formulation and dosing regimen patents.

4. How does patent expiry translate into market entry risk?
   Entry risk increases when core composition patents expire and remaining method/formulation patents are either narrow, hard to enforce, or design-aroundable.

5. What clinical endpoints most influence reimbursement for bile acid therapies?
   Disease activity and pruritus endpoints that map to bile acid physiology, commonly including serum bile acids, ALP, and itch score measures.

---

References

[1] U.S. Food and Drug Administration. Orange Book (Drugs Approved for Marketing With Therapeutic Equivalence Evaluations). https://www.accessdata.fda.gov/scripts/cder/daf/
[2] European Medicines Agency. EPAR pages and product information for bile-acid pathway medicines. https://www.ema.europa.eu/
[3] United States Patent and Trademark Office. Patent Public Search (for bile-acid pathway mechanism and compound family searches). https://ppubs.uspto.gov/
[4] World Intellectual Property Organization. Patentscope (for family-level tracking of bile-acid pathway inventions). https://patentscope.wipo.int/